Masimo (NASDAQ:MASI) Issues FY25 Earnings Guidance

Masimo (NASDAQ:MASI) issued an update on its FY25 earnings guidance on Thursday morning. The company provided EPS guidance of $4.90-$5.10 for the period, compared to the consensus EPS estimate of $4.74.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on MASI. Wells Fargo & Company boosted their target price on shares of Masimo from $171.00 to $193.00 and gave the company an “overweight” rating in a research note on Wednesday, December 11th. Stifel Nicolaus reissued a “buy” rating and set a $190.00 price objective (up previously from $170.00) on shares of Masimo in a research note on Friday, November 22nd. Needham & Company LLC reissued a “hold” rating on shares of Masimo in a research note on Wednesday, November 6th. BTIG Research raised their price objective on Masimo from $166.00 to $170.00 and gave the stock a “buy” rating in a report on Monday, October 14th. Finally, Piper Sandler upped their target price on Masimo from $180.00 to $210.00 and gave the company an “overweight” rating in a research note on Wednesday, December 18th. Three research analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $179.67.

Masimo Trading Up 3.6 %

MASI stock opened at $172.07 on Thursday. The company has a quick ratio of 1.11, a current ratio of 2.01 and a debt-to-equity ratio of 0.50. The company has a market cap of $9.21 billion, a price-to-earnings ratio of 118.67 and a beta of 1.01. The business has a fifty day simple moving average of $168.86 and a 200-day simple moving average of $139.54. Masimo has a 52 week low of $101.61 and a 52 week high of $180.97.

Masimo (NASDAQ:MASI) last posted its quarterly earnings results on Tuesday, November 5th. The medical equipment provider reported $0.98 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.84 by $0.14. The firm had revenue of $504.60 million during the quarter, compared to the consensus estimate of $502.87 million. Masimo had a return on equity of 14.98% and a net margin of 3.85%. The firm’s quarterly revenue was up 5.4% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.63 earnings per share. On average, equities research analysts expect that Masimo will post 4.03 EPS for the current year.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.